IMNM

Immunome Inc. IMNM

NasdaqMid CapHealthcare

13F Pro quality score

Rank #2,770 of 3,064

Why it scores 25Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$0

Quarter to Jun 30

Net income

$-73.13M

Quarter to Jun 30

Free cash flow

$-63.87M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$2.50B total
T. Rowe Price Investment Management, Inc.
$416.95M+20.2%
FMR LLC
$359.97M+0.1%
BlackRock, Inc.
$186.59M+7.8%
STATE STREET CORP
$116.43M+1.8%
WELLINGTON MANAGEMENT GROUP LLP
$110.40M+10.1%
Redmile Group, LLC
$104.08M-11.6%
PRIMECAP MANAGEMENT CO/CA/
$97.08M-4.3%
VANGUARD CAPITAL MANAGEMENT LLC
$96.44M+2.7%
DRIEHAUS CAPITAL MANAGEMENT LLC
$92.09M+6.0%
Enavate Sciences GP, LLC
$76.58M0.0%
GEODE CAPITAL MANAGEMENT, LLC
$58.39M+7.6%
MORGAN STANLEY
$51.02M-15.3%
SILVERARC CAPITAL MANAGEMENT, LLC
$42.74M+9.0%
JPMORGAN CHASE & CO
$38.99M-33.5%
PRICE T ROWE ASSOCIATES INC /MD/
$37.58M-38.0%
Sofinnova Ventures Inc
$36.45M+1.1%
READYSTATE ASSET MANAGEMENT LP
$34.03M+23.3%
GOLDMAN SACHS GROUP INC
$32.05M+37.3%
VANGUARD PORTFOLIO MANAGEMENT LLC
$28.58M+34.0%
PRINCIPAL FINANCIAL GROUP INC
$28.55M-2.1%
BNP Paribas Asset Management Holding S.A.
$26.49M+13.9%
Woodline Partners LP
$21.20M-36.5%
NORTHERN TRUST CORP
$20.52M+7.7%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$18.78M+4.0%
MetLife Investment Management, LLC
$18.20M+1438.0%
See all 204 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/IMNM

Earnings Per Share

13fpro.ai/company/IMNM

Loading ratio trend…

IMNM key financials by period

Reported revenue, net income and operating margin by fiscal year, from Immunome Inc.'s annual filings on SEC EDGAR.

Immunome Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$6.9M$-212.4M—
FY 2024$9.0M$-293.0M—
FY 2023$14.0M$-106.8M—
Source: IMNM filings on SEC EDGAR →

IMNM insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Immunome Inc. (IMNM): stock profile, AI score and financials

Immunome Inc. (IMNM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IMNM at 25.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,770 of 3,064 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (5.9) and earnings quality (19.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Immunome Inc. reports net income of $-73.1M, free cash flow of $-63.9M. Top institutional holders of IMNM by reported 13-F value include T. Rowe Price Investment Management, FMR, BlackRock, based on the most recent SEC filings. IMNM trades on the Nasdaq exchange and files with the SEC under CIK 1472012. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMNM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immunome Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1472012 →